ライフサイエンスコーパス: immune-related

1 nregulated pathways in metastases are mainly immune-related.

2 t could lead to therapeutics for this morbid immune related adverse event.

3 Given the frequency of immune related adverse events and increasing use of ICB,

4 their use can also be associated with unique immune-related adverse effects (irAEs).

5 anticancer therapies, including neurological immune-related adverse effects (nirAEs) that can manifes

6 Despite increasing reports of immune-related adverse effects related to ipilimumab the

7 er, these new treatments are associated with immune-related adverse effects that can involve differen

8 tentially providing key information to limit immune-related adverse effects.

9 safety defined as any grade 3 or greater or immune-related adverse event (AE) and the change in HIV-

10 ) with retinal venulitis is a newly reported immune-related adverse event (irAE) that further expands

11 primary outcome assessed was any "new onset" immune-related adverse event (IRAE).

12 isms responsible for the development of this immune-related adverse event and to ultimately predict o

13 Vitiligo, a clinically visible immune-related adverse event could be associated with cl

14 Detailed study of ophthalmic immune-related adverse events (AEs), including determina

15 oduces a diverse and unpredictable number of immune-related adverse events (IRAE).

16 gnosis and timely management of neurological immune-related adverse events (irAE-N).

17 However, immune-related adverse events (irAEs) and the risk of in

18 sed use of cancer immunotherapy, a number of immune-related adverse events (irAEs) are being identifi

19 ndard treatment for metastatic melanoma, but immune-related adverse events (irAEs) are common and can

20 esponses in numerous metastatic cancers, but immune-related adverse events (irAEs) complicate and lim

21 However, immune-related adverse events (irAEs) have emerged as fr

22 Immune-related adverse events (irAEs) of any grade with

23 se treatments commonly evoke a wide range of immune-related adverse events (irAEs) that can affect an

24 quency of autoimmune flares and conventional immune-related adverse events (irAEs), and efficacy, in

25 al-world frequency, phenotypes, co-occurring immune-related adverse events (irAEs), and long-term out

26 Immune-related adverse events (irAEs), caused by anti-PD

27 ckpoint inhibitors have been associated with immune-related adverse events (irAEs), immune toxicities

28 utcomes were: objective response rate (ORR), immune-related adverse events (irAEs), progression free

29 vances is the emergence of a new spectrum of immune-related adverse events (irAEs), which are often d

30 ients receiving these treatments may develop immune-related adverse events (irAEs).

31 nhibition, and some develop life-threatening immune-related adverse events (irAEs).

32 xperienced dose-limiting toxicity (DLT) from immune-related adverse events (irAEs).

33 inflammatory responses and toxicities termed immune-related adverse events (irAEs).

34 sed use has resulted in increased reports of immune-related adverse events (irAEs).

35 ne surveillance, but often at the expense of immune-related adverse events (irAEs).

36 e adds to the expanding literature regarding immune-related adverse events associated with ipilimumab

37 iated with numerous cancers, but high-grade, immune-related adverse events can occur, particularly wi

38 potent antitumor efficacy, it also leads to immune-related adverse events in cancer patients.

39 The most common grade 3-4 immune-related adverse events in the ipilimumab group we

40 A variety of dermatologic immune-related adverse events including maculopapular er

41 ts are typically well tolerated, the risk of immune-related adverse events increases with combination

42 Immune-related adverse events led to treatment discontin

43 suppressing agents for severe (grade 3 or 4) immune-related adverse events like neurotoxicity and pne

44 Grade 3 or 4 immune-related adverse events occurred in 36% of patient

45 Extrarenal immune-related adverse events occurred in 43% of patient

46 Immune-related adverse events of grade 3 or 4 occurred i

47 nt, low patient response rates and potential immune-related adverse events remain two major challenge

48 to checkpoint protein inhibitors that induce immune-related adverse events that are autoinflammatory

49 These therapies mediate immune-related adverse events that may mimic or amplify

50 Concomitant extrarenal immune-related adverse events were associated with worse

51 ontinued to receive ipilimumab, grade 3 or 4 immune-related adverse events were observed exclusively

52 The most common grade 3-4 immune-related adverse events were rash (11 [8%] of 141

53 However, the prevalence of severe immune-related adverse events with CTLA4 and PD1 pathway

54 There were more immune-related adverse events with ipilimumab than with

55 Six patients had seven grade 3-4 immune-related adverse events with two cases of rash, tw

56 olved in the pathophysiological processes of immune-related adverse events, and limits potential adve

57 th a unique pattern of adverse events called immune-related adverse events, and occasionally, unusual

58 served 6 of 28 patients (21%) with grade >=3 immune-related adverse events, consisting of asymptomati

59 Immune-related adverse events, including one death, were

60 23 (47%) of 49 patients had immune-related adverse events, of whom nine (39%) had as

61 to immunotherapy and simultaneously identify immune-related adverse events, there are several challen

62 ine (39%) had asymptomatic grade 3-4 hepatic immune-related adverse events, which were reversible wit

63 e monoclonal antibodies, which often inflict immune-related adverse events.

64 une activation in tumor tissues for reducing immune-related adverse events.

65 treating patients with severe and refractory immune-related adverse events.

66 progression and in detecting and monitoring immune-related adverse events.

67 nt immune activation while avoiding limiting immune-related adverse events.

68 in, gastrointestinal, endocrine, and hepatic immune-related adverse events.

69 3 patients with new lesions associated with immune-related adverse events.

70 Usually, side effects are immune-related adverse events.

71 mumab group, 5 patients (1.1%) died owing to immune-related adverse events.

72 nistration of IL-12 has been associated with immune-related adverse events.

73 mor immunity while reducing the incidence of immune-related adverse events.

74 y available immunotherapies and many develop immune-related adverse events.

75 nsidering anti-TNFalpha treatment for severe immune-related adverse events.

76 tients discontinued pembrolizumab because of immune-related adverse events.

77 had a significantly high risk for all-grade immune-related adverse events.

78 drugs to treat severe and steroid refractory immune-related adverse events.

79 tients required dose interruption because of immune-related adverse events: one (4%) of 25 each had g

80 e utility of ICI therapy has been limited by immune-related adverse reactions (irAEs) affecting multi

81 symptomatic hypophysitis (a protocol-defined immune-related AE) was identified 266 days after BMS-936

82 anterior uveitis, the most common ophthalmic immune-related AE, were 8209 per 100 000 for ipilimumab

83 t (AE), and 40% at least 1 grade 2 or higher immune-related AE.

84 fied, 112 of whom demonstrated an ophthalmic immune-related AE.

85 f chemoradiotherapy adverse events (AEs) and immune-related AEs (irAEs).

86 derived by comparing incidence of ophthalmic immune-related AEs after ICIs versus rates of the same o

87 nstrated high recurrence rates of ophthalmic immune-related AEs after initiating ICIs (up to 51.1%).

88 Rates of ophthalmic immune-related AEs among patients receiving ICI therapy

89 are is important because rates of ophthalmic immune-related AEs are elevated compared with ocular com

90 Rates of ophthalmic immune-related AEs in patients with a past history of oc

91 on (21% and 10%, respectively); grade 3 or 4 immune-related AEs included hepatitis (0% and 13%, respe

92 Patients with select ophthalmic immune-related AEs were identified by International Clas

93 Incidence of ophthalmic immune-related AEs within 1 year after initiation of ICI

94 (8%) were treated with systemic steroids for immune-related AEs.

95 s were of all treatment-related AEs, select (immune-related) AEs, time to onset and resolution, and u

96 sis to show that transcriptional profiles of immune-related and lysosomal risk factor genes predict s

97 okine signaling and upstream inflammation in immune-related and other chronic diseases.

98 w that integration of functional genomic and immune-related annotations, together with knowledge of n

99 hich highlights the relevance of considering immune-related aspects of different pre-clinical models.

100 The current review focuses on immune-related aspects of non-murine models, including d

101 nctional analysis of these miRNA targets, 12 immune-related biological processes were found to be sig

102 l mucosa, and transcriptional differences in immune-related biological processes.

103 rview of the current therapeutic success and immune-related burden of secondary effects of checkpoint

104 Incidence of infection-related and immune-related cancer was higher during kidney function

105 mmunotherapy treatment to reduce the risk of immune-related cardiotoxicity.

106 Prominent immune-related cargos of plant trafficking pathways are

107 nstrate a novel enrichment method to capture immune-related cells from clinical airway secretions usi

108 These data demonstrate that immune-related changes in schizophrenia extend to dopami

109 ent with baseline psoriasis died of presumed immune-related colitis after a 1-week delay prior to rep

110 ombocytopenia (HIT), a difficult-to-diagnose immune-related complication that often leads to limb isc

111 e crucial given the risk of life-threatening immune-related complications associated with these thera

112 FA patients have high susceptibility to immune-related complications such as infection and postt

113 al visits and admissions and therapy-induced immune-related complications without compromising cancer

114 evated incidence rate ratios (IRRs) for many immune-related conditions in survivors of DLBCL compared

115 dysfunction occurs in several autoimmune and immune-related conditions, including Sjogren syndrome (S

116 ety of human diseases, especially cancer and immune-related conditions.

117 tion was employed to measure mRNA levels for immune-related cytokines and transcriptional regulators,

118 In addition, a significant number of immune related DEGs were identified.

119 s in survival between these two tumor types, immune-related differences in cell content are potential

120 on signatures predicted clinical outcome and immune-related differences in the microenvironment.

121 xpression of lipid metabolism genes revealed immune-related differentially expressed lipid metabolic

122 tified in genome-wide association studies of immune-related disease, suggesting that both alleles are

123 elopment of new clinical therapies targeting immune-related disease.

124 roxychloroquine (HCQ) are used to treat auto-immune related diseases such as rheumatoid arthritis (RA

125 t of the immune system, immune responses and immune-related diseases alter circRNA expression.

126 in the development of therapies for managing immune-related diseases and cancer.

127 is given to the skin because many different immune-related diseases occur in the skin.

128 Imbalance, however, has been linked to immune-related diseases such as allergy and cancer, char

129 juries, mental and behavioral disorders, and immune-related diseases such as noninfective enteritis a

130 e as well as in therapeutic applications for immune-related diseases.

131 long-term therapeutic benefits in a range of immune-related diseases.

132 ctivation of immune cells and their roles in immune-related diseases.

133 could be a potential therapeutic target for immune-related diseases.

134 vary considerably in their susceptibility to immune-related diseases.

135 is important for understanding and treating immune-related diseases.

136 new immunomodulatory drugs in the therapy of immune-related diseases.

137 rtcut to identifying potential mechanisms of immune-related diseases.

138 d disease mechanisms for psoriasis and other immune-related diseases.

139 s mediating susceptibility to infectious and immune-related diseases.

140 n the initiation and development of adaptive immune related disorders.

141 on and pleiotropy with other psychiatric and immune-related disorders were estimated.

142 linked polyubiquitin have been implicated in immune-related disorders.

143 ved between PTSD and 6 mental disorders or 9 immune-related disorders.

144 lammatory in vitro, are also associated with immune-related epigenetic markers.

145 Understanding the mechanisms by which immune-related events in the periphery can influence bra

146 Immune-related events in the periphery can remotely affe

147 ese observations support the hypothesis that immune-related exposures, especially atopy, are associat

148 erstanding of how genetic, environmental and immune-related factors contribute to a prominent (but no

149 eukaryotic life and play a broader, possibly immune-related function outside venom.

150 Six genes with immune related functions have additional copies in the i

151 sociated genes are significantly enriched in immune-related functions and closer with each other in t

152 eled top-to-bottom approach and demonstrated immune-related functions for them, further validating th

153 Many of these genes have immune-related functions involved in signaling pathways,

154 e reconnoitering, as well as a number of non-immune-related functions necessary for proper embryogene

155 nities to mannose-binding lectin, suggesting immune-related functions of paucimannosylation in activa

156 , and describe how novel gene regulatory and immune-related functions of these ncRNAs may impact the

157 depressive disorder were enriched for innate immune-related functions, coded for nonrandom protein-pr

158 downregulation of matrisome, cell cycle and immune related gene sets in Lcn2(-/-) mice exposed to CC

159 We identified an immune-related gene expression pattern in liver tissues

160 We investigated immune-related gene expression patterns in liver tissues

161 formation has been associated with a unique immune-related gene expression signature composed of dis

162 1b(+)/CD45(hi)) revealed a unique pattern of immune-related gene expression that was dependent on str

163 ristics, including copy number variation and immune-related gene expression, we demonstrate our metho

164 However, a robust map of immune-related gene networks in circulating human cells,

165 ation of histone H3 at lysine 4 (H3K4me3) on immune-related gene promoters underlies robust transcrip

166 ic signaling and modulates the expression of immune related genes in peripheral leukocytes and immune

167 Five polyomavirus genes and seven immune-related genes (five associated with BKVN and two

168 These loci are enriched for immune-related genes (such as OAS1/2/3, TLR1/6/10, and T

169 eads to a significant upregulation of innate immune-related genes and an increase in the number of ce

170 ated expression of overlapping sets of glial/immune-related genes and female-biased expression of neu

171 are integrated with the regulation of other immune-related genes are not known.

172 s are mostly modulated at the initial stage; immune-related genes are specifically affected as the lo

173 conditional deletion of Tet1 and found that immune-related genes are the most highly dysregulated.

174 ccurrence of inherited damaging mutations in immune-related genes compared to patients with solitary

175 A total of 149 immune-related genes in 20 gene families were identified

176 ssociation studies have highlighted multiple immune-related genes in association with Alzheimer's dis

177 study identified a set of glucocorticoid and immune-related genes in association with parental Holoca

178 show that HPV can suppress the expression of immune-related genes in neighboring fibroblasts in a thr

179 identify signatures of positive selection on immune-related genes in the ancient but not the modern g

180 e studies suggesting that high expression of immune-related genes indicates active and targetable dis

181 in induction, we detected an upregulation of immune-related genes involved in PD-1-PD-L1 (programmed

182 ical pacemaker neurons express a rich set of immune-related genes mediating their interaction with th

183 ancer 730-Immune Panel, and we identified 23 immune-related genes or signatures linked to response an

184 and chemokine (C-C motif) ligand 20 (CCL20), immune-related genes previously described in genome-wide

185 age, detoxification, nutrient recycling, and immune-related genes relevant for facilitating interacti

186 FBR1, the proto-oncogene MYB as well as many immune-related genes such as CCR7 and FCRL3, reinforcing

187 characterization of several inborn errors of immune-related genes that underlie inherited human susce

188 een distantly related cell types such as the immune-related genes that were similarly expressed in im

189 Expression profiling for immune-related genes was performed on select HIV-positiv

190 city estimates corroborated the finding that immune-related genes were activated in the LV but not in

191 ting and activated T cells, identifying many immune-related genes with differential expression.

192 less complex genomic profile and upregulated immune-related genes, allowing the possibility of immuno

193 p-scoring upregulated module was enriched in immune-related genes, consistent with activation of micr

194 he GSCs tested were poised for expression of immune-related genes, including CD276 We demonstrate tha

195 ic background, and significant enrichment in immune-related genes, reflecting long-term balancing sel

196 ffected the transcriptional response of most immune-related genes, with age effects being more stimul

197 variants that dysregulate the expression of immune-related genes.

198 A expression of a subset of inflammatory and immune-related genes.

199 o synonymous mutation rate even greater than immune-related genes.

200 d, immune-absent) according to expression of immune-related genes.

201 s gene expression of serotonin receptors and immune-related genes.

202 underscored by the recent identification of immune-related genetic risk factors for AD, including co

203 genes in human are predominantly enriched in immune related GO terms while viral HGT genes are tend t

204 at genes with IM promoters were enriched for immune-related GO categories; this enrichment was not ob

205 Immune-related grade 3 to 4 AEs occurred in 31% and 2% o

206 patients with stage IV and III melanoma.(1) Immune-related hepatotoxicity is reported in 2-10% of pa

207 tic variants, environmental triggers such as immune-related, infection-related, toxic and haemodynami

208 ion or a long-lasting response to a prenatal immune-related insult.

209 recent study with high-density genotyping of immune-related loci in individuals with Asian ancestry i

210 d its dysregulation has been associated with immune-related malignancies.

211 or its ability to semiquantify messenger RNA immune-related markers directly from blood, using the Fi

212 Subtype associations for several immune-related markers-including PD1, PDL1, CD3 and CD8-

213 nervous system (CNS) is endowed with several immune-related mechanisms that contribute to its protect

214 The correlation between immune-related modules and schizophrenia was replicated

215 udies demonstrated surprising dual roles for immune-related molecules and their effector mechanisms d

216 f transcription, with global upregulation of immune-related mRNA transcripts following infection and

217 e BSC group (P = .43), the most common being immune related, nonfebrile neutropenia, gastrointestinal

218 Adverse events that were potentially immune-related occurred in 54% of participants; most wer

219 imilar levels as full-length Md1 in the main immune-related organs of zebrafish and are highly induce

220 Immune-related partial response was observed in another

221 h immune protection, without the significant immune-related pathogenic risk associated with type I IF

222 f immune homeostasis comes from a variety of immune-related pathologies, such as autoimmune diseases,

223 exhibits countless genetic associations with immune-related pathologies.

224 ibitor (ICI) therapy is often accompanied by immune-related pathology, with an increasing occurrence

225 systemically and specially in the process of immune related pathways.

226 Alterations in immune-related pathways are common hallmarks of cancer.

227 cuss studies that validate the disruption of immune-related pathways as an important mechanism of tox

228 is revealed enrichment of cell migration and immune-related pathways in CTC clusters, suggesting surv

229 ce lung tissue gene expression and implicate immune-related pathways in mediating the observed effect

230 Immune-related pathways included leukocyte trafficking a

231 y (GO) analyses revealed lower expression of immune-related pathways such as chemokine receptor activ

232 trix and transport, as well as oncogenic and immune-related pathways transduced by plasma membrane re

233 ene signature reflecting bone remodeling and immune-related pathways was upregulated in high compared

234 d, blood, and brain tissues are enriched for immune-related pathways, consistent with other expressio

235 dramatic decreases in expression of numerous immune-related pathways, including Ag presentation and T

236 s with immunologic function were mapped into immune-related pathways.

237 of cigarette smoking revealed enrichment for immune-related pathways.

238 markers (e.g. IL10), and modulated multiple immune-related pathways.

239 st immunity to treat cancers, unconventional immune-related phenomena are encountered in terms of tum

240 y be successfully used for ASD patients with immune-related phenotypes.

241 We describe the chronology of immune-related problems that culminated in allograft nec

242 ysis showed radiation-specific enrichment of immune-related processes, and T cell receptor sequencing

243 nsplantation relapses and highly enriched in immune-related processes, including T cell costimulation

244 on as biological switches controlling mainly immune-related processes.

245 fied the emerging role of PTEN in modulating immune-related processes.

246 shown to exert metabolic, inflammatory, and immune-related properties and thereby could be implicate

247 ghly expressed in microglia and highlight an immune-related protein-protein interaction network enric

248 o characterize expression of MHCII and other immune related proteins in tumor epithelial versus strom

249 Immune-related proteins are covered by updates from IPD-

250 transcripts encoding antioxidant enzymes and immune-related proteins were typically higher in colonie

251 wed pleiotropic effects on the production of immune-related proteins, on metabolic traits such as lip

252 nflammatory cytokines, chemokines, and other immune-related proteins.

253 asize that altering the function of a single immune-related receptor can dramatically change the repa

254 essments were evaluated by investigators per immune-related RECIST.

255 o become differentially regulated by the key immune-related redox cue, NO.

256 Finally, we assess future directions for immune-related research in neurodegeneration and potenti

257 ment response on CT using RECIST 1.1 and the immune-related response criteria (irRC) and on (18)F-FDG

258 vival and best overall response measured per immune-related response criteria (irRC) and Response Eva

259 s, and the response pattern according to the immune-related response criteria (irRC).

260 nary toxicity were prospectively assessed by Immune-related Response Criteria and Common Terminology

261 y end points were objective response rate by immune-related response criteria and safety.

262 ary endpoints included objective response by immune-related response criteria in all patients who wer

263 -month disease control rate according to the immune-related response criteria served as the primary e

264 tor-assessed objective response according to immune-related response criteria was achieved for 41 of

265 se (PR) using RECIST criteria (two PRs using immune-related response criteria), and three instances o

266 CR was defined per investigator assessment, immune-related response criteria, and potential predicto

267 investigator-assessed response according to immune-related response criteria.

268 response rate evaluated by investigators per immune-related response criteria.

269 2%, with a complete response rate of 33% per immune-related response criteria.

270 ion Criteria in Solid Tumors version 1.1 and immune-related response criteria.

271 ies, had measurable disease according to the immune-related Response Evaluation Criteria In Solid Tum

272 e current methods for imaging evaluations of immune-related responses and toxicities are reviewed alo

273 Radiotherapy induces immune-related responses in cancer patients by various m

274 Proof-of-concept is established for immune-related rheumatoid arthritis and inflammatory bow

275 ious adverse events (SAEs), five of whom had immune-related SAEs, including two with adrenal insuffic

276 Although the number of available immune-related scRNA-seq datasets increases rapidly, the

277 e, we created the JingleBells repository for immune-related scRNA-seq datasets ready for analysis and

278 collected the raw data of publicly available immune-related scRNA-seq datasets, aligned the reads to

279 and treatment is often accompanied by severe immune-related side effects, suggesting the importance o

280 ciliary activity in vivo and alters multiple immune-related signaling cascades.

281 sceptible patients show early alterations in immune-related signaling pathways, epigenetic modulation

282 erferon-gamma, T-cell receptor, and expanded immune-related signaling pathways.

283 ell as expression of genes involved in other immune-related signaling pathways.

284 We identified immune-related signatures correlating with clinical bene

285 dicates a way forward to discover prognostic immune-related subsets in primary melanoma and to unders

286 identified two main subtypes of ILCs: (i) an immune related subtype with mRNA up-regulation of PD-L1,

287 anization, response to wounding, and several immune-related terms.

288 neurodegeneration and potential avenues for immune-related therapies.

289 Associated genes are strongly expressed in immune-related tissues and cell types (spleen, liver, an

290 inter-tissue repertoire similarities across immune-related tissues are also evaluated.

291 e related genes in peripheral leukocytes and immune-related tissues of dairy calves.

292 ts with advanced melanoma but cause frequent immune-related toxic effects.

293 ministration of R848 often results in strong immune-related toxicities while having limited therapeut

294 Footprinting analysis revealed that immune-related transcription factors (TFs), such as NF-k

295 e chromatin, and bear recognition motifs for immune-related transcription factors.

296 These alternations in many immune-related transcripts and biological processes resu

297 ight be associated with nutrient uptake, and immune-related transcripts including antimicrobial pepti

298 Recent breakthroughs in novel immune-related treatment strategies for cancer have spur

299 Immune-related treatment-related events occurred in 22 p

300 important role in objectively characterizing immune-related tumor responses and progression and in de